In recent days, researchers from Lancaster University have developed a new drug that can help inhibit the onset of early Alzheimer's disease and is now in clinical trials.
In recent years, the number of individuals suffering from dementia has been increasing. There are currently 850,000 dementia patients in the UK, and researchers predict that the number of people with dementia will reach 1 million by 2021. The most common dementia is Alzheimer's. Alzheimer's disease begins when beta amyloid forms aging plaques and accumulates in the brain. This plaque damages nerve cells in the brain and causes memory loss and confusion.
Researcher David Allsop said that we have developed a new drug in the laboratory that can effectively reduce the number of aging plaques in the brain and also reduce brain inflammation and oxidative damage associated with Alzheimer's disease; The patent has been patented for the drug and it has entered the clinical trial phase, and if the drug passes regulatory barriers, it will be approved for the treatment of Alzheimer's disease.
There are many individuals with mild amnesia who develop Alzheimer's disease because aging spots form slowly in the brain for many years before the patient's symptoms appear. The researcher's goal is to use this new drug to effectively block Broken aging plaque damage to the brain. Steve Higham said that the inhibition of Alzheimer's disease is very important for millions of people around the world, and there is an urgent need for new treatments for dementia, and this study has also provided some support for accelerating the development of new therapies. Help and ideas.
Finally, the researchers said that the Alzheimer's Association will continue to invest in the development of new drugs to help patients around the world, and the new drugs developed by researchers in this article can effectively inhibit the formation of aging plaques in patients' brains. It has brought great hopes for the effective inhibition of the development of the disease. At present, the drug has entered the stage of clinical trial. The researchers hope that the later results or new research data for the development of new therapies for the treatment of Alzheimer's disease. help.
In recent years, the number of individuals suffering from dementia has been increasing. There are currently 850,000 dementia patients in the UK, and researchers predict that the number of people with dementia will reach 1 million by 2021. The most common dementia is Alzheimer's. Alzheimer's disease begins when beta amyloid forms aging plaques and accumulates in the brain. This plaque damages nerve cells in the brain and causes memory loss and confusion.
Researcher David Allsop said that we have developed a new drug in the laboratory that can effectively reduce the number of aging plaques in the brain and also reduce brain inflammation and oxidative damage associated with Alzheimer's disease; The patent has been patented for the drug and it has entered the clinical trial phase, and if the drug passes regulatory barriers, it will be approved for the treatment of Alzheimer's disease.
There are many individuals with mild amnesia who develop Alzheimer's disease because aging spots form slowly in the brain for many years before the patient's symptoms appear. The researcher's goal is to use this new drug to effectively block Broken aging plaque damage to the brain. Steve Higham said that the inhibition of Alzheimer's disease is very important for millions of people around the world, and there is an urgent need for new treatments for dementia, and this study has also provided some support for accelerating the development of new therapies. Help and ideas.
Finally, the researchers said that the Alzheimer's Association will continue to invest in the development of new drugs to help patients around the world, and the new drugs developed by researchers in this article can effectively inhibit the formation of aging plaques in patients' brains. It has brought great hopes for the effective inhibition of the development of the disease. At present, the drug has entered the stage of clinical trial. The researchers hope that the later results or new research data for the development of new therapies for the treatment of Alzheimer's disease. help.
Lower Blood Sugar Plant Extract
Lower Blood Sugar Plant Extract,Inonotus Obliquus Extract,Chaga Extract Powder,Chaga Mushroom Extract Powder Polysaccharide
Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.sinuotebio.com